Noninvasive Testing for Colorectal Cancer: A Review

OBJECTIVES:Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States. Endoscopic screening is now in favor and its use is increasing, but overall participation rates are poor. A substantial percentage of the population will likely continue to resist endoscopic screening. As such, a noninvasive biomarker for the early detection of CRC remains a priority. Herein, we (i) review the currently available noninvasive screening markers for the early detection of CRC, (ii) discuss newer markers that have undergone preliminary testing, and (iii) introduce and explain potentially promising markers of the future.METHODS:The published literature on markers for early detection of CRC was identified using a MEDLINE/PubMed search with secondary review of cited publications.RESULTS:Noninvasive testing for CRC is most advanced in testing for stool fecal occult blood, globin, or DNA mutations. Study of abnormal mucins has also been explored. Research for serum-based markers is just beginning and includes serum proteomics, nuclear matrix proteins, and serum DNA testing.CONCLUSIONS:Serial guaiac-based fecal occult blood testing (FOBT) is simple, inexpensive, and proven effective at reducing mortality from CRC. Immunochemical fecal occult blood tests facilitate compliance and offer improved specificity, but at increased cost in comparison to FOBT. Fecal DNA testing may provide enhanced sensitivity for detection of CRC in comparison with FOBT, but its high cost limits its use for generalized screening. Rectal mucin testing requires additional evaluation to determine its sensitivity and specificity in comparison with guaiac-based FOBT. Serum tests, such as proteomics, nuclear matrix proteins, and serum DNA, are still in their infancy, but remain a hope for the future.

[1]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[2]  J. Ho,et al.  A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population , 2003, Alimentary pharmacology & therapeutics.

[3]  Y. Nagamachi,et al.  Evaluation of a new test for colorectal neoplasms: a prospective study of asymptomatic population. , 1993, Cancer biotherapy.

[4]  K. Kinzler,et al.  Detection of proximal colorectal cancers through analysis of faecal DNA , 2002, The Lancet.

[5]  P. Brandtzaeg,et al.  Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes. Immunofluorescence and immunoperoxidase staining features in comparison with lysozyme and lactoferrin. , 1985, American journal of clinical pathology.

[6]  Screening for colorectal cancer: recommendation and rationale. , 2002, American family physician.

[7]  M. von Knebel Doeberitz,et al.  Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry-based detection of microsatellite instabilities in coding DNA sequences: a novel approach to identify DNA-mismatch repair-deficient cancer cells. , 2003, Clinical chemistry.

[8]  Yonggoo Kim,et al.  Gastrointestinal tract cancer screening using fecal carcinoembryonic antigen. , 2003, Annals of clinical and laboratory science.

[9]  D. Ransohoff.  Rules of evidence for cancer molecular-marker discovery and validation , 2004, Nature Reviews Cancer.

[10]  Daniel S. Miller,et al.  The annual report to the nation on the status of cancer, 1973–1997, with a special section on colorectal cancer , 2000, Cancer.

[11]  T. Mancuso,et al.  Molecular Detection of Codon 12 K-RAS Mutations in Circulating DNA from Serum of Colorectal Cancer Patients , 2000, The International journal of biological markers.

[12]  D. Ahlquist.  Stool-based DNA tests for colorectal cancer: clinical potential and early results. , 2002, Reviews in gastroenterological disorders.

[13]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[14]  Y. Kodera,et al.  Detection of Tumor DNA in Serum of Colorectal Cancer Patients , 2002, Japanese journal of cancer research : Gann.

[15]  P. A. Dawson,et al.  An ultrastructural and histochemical study of the mucous membrane adjacent to and remote from carcinoma of the colon , 1976, Cancer.

[16]  E. Petricoin,et al.  Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.

[17]  E. Petricoin,et al.  Use of proteomic patterns to screen for gastrointestinal malignancies. , 2004, Surgery.

[18]  T. Church,et al.  Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. , 1999, Journal of the National Cancer Institute.

[19]  S. Moss,et al.  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer , 1989, The Lancet.

[20]  J. Lupton,et al.  Quantification of human intestinal gene expression profiles using exfoliated colonocytes: a pilot study , 2003, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[21]  C. Boland,et al.  Alterations in human colonic mucin occurring with cellular differentiation and malignant transformation. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[22]  K. Ahmed,et al.  Nuclear matrix proteins as malignant markers in squamous cell carcinoma of the head and neck. , 1997, Archives of otolaryngology--head & neck surgery.

[23]  P. Rozen,et al.  Performance Characteristics and Comparison of Two Immunochemical and Two Guaiac Fecal Occult Blood Screening Tests for Colorectal Neoplasia , 1997, Digestive Diseases and Sciences.

[24]  D. Rockey,et al.  Relative frequency of upper gastrointestinal and colonic lesions in patients with positive fecal occult-blood tests. , 1998, The New England journal of medicine.

[25]  D. Ransohoff,et al.  Suggested technique for fecal occult blood testing and interpretation in colorectal cancer screening. American College of Physicians. , 1997, Annals of internal medicine.

[26]  D. Ahlquist,et al.  Stool screening for colorectal cancer: evolution from occult blood to molecular markers. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[27]  V. Vasioukhin,et al.  K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. , 1997, Gastroenterology.

[28]  D. Chan,et al.  Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.

[29]  S. Syngal.  Stool DNA analysis for the detection and follow-up of Colorectal Cancer (CRC) and Advanced Adenomas (AA): sensitivity in a prospective series , 2002 .

[30]  J. Terdiman,et al.  Colorectal cancer screening: scientific review. , 2003, JAMA.

[31]  J. Cummings,et al.  Quantitation of DNA from exfoliated colonocytes isolated from human stool surface as a novel noninvasive screening test for colorectal cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  T. Ørntoft,et al.  Comparative immunoperoxidase demonstration of T-antigens in human colorectal carcinomas and morphologically abnormal mucosa. , 1985, Cancer research.

[33]  A. Shamsuddin,et al.  Expression of carcinoembryonic antigen, T-antigen, and oncogene products as markers of neoplastic and preneoplastic colonic mucosa. , 1987, Human pathology.

[34]  R. Day,et al.  Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  M. Duffy,et al.  Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? , 2001, Clinical chemistry.

[36]  D. Ahlquist.  Fecal occult blood testing for colorectal cancer. Can we afford to do this? , 1997, Gastroenterology clinics of North America.

[37]  L M Schuman,et al.  Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. , 1993, The New England journal of medicine.

[38]  P. Rozen,et al.  Eliminating the Need for Dietary Restrictions When Using a Sensitive Guaiac Fecal Occult Blood Test , 1999, Digestive Diseases and Sciences.

[39]  E. Diamandis.  Re: diagnostic potential of serum proteomic patterns in prostate cancer. , 2004, The Journal of urology.

[40]  T. Miller,et al.  Detection of nuclear matrix proteins in serum from cancer patients. , 1992, Cancer research.

[41]  B. Trump,et al.  Colon epithelium. IV. Human colon carcinogenesis. Changes in human colon mucosa adjacent to and remote from carcinomas of the colon. , 1981, Journal of the National Cancer Institute.

[42]  P. Gold,et al.  The radioimmunoassay of circulating carcinoembryonic antigen of the human digestive system. , 1969, Proceedings of the National Academy of Sciences of the United States of America.

[43]  D. Ahlquist,et al.  DNA integrity as a potential marker for stool-based detection of colorectal cancer. , 2003, Clinical chemistry.

[44]  D. Rockey,et al.  Detection of upper gastrointestinal blood with fecal occult blood tests , 1999, American Journal of Gastroenterology.

[45]  M. Duffy,et al.  Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. , 2003, European journal of cancer.

[46]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[47]  R. Schoen,et al.  Colon cancer specific nuclear matrix protein alterations in human colonic adenomatous polyps , 2004, Journal of cellular biochemistry.

[48]  D. S. Coffey,et al.  Tissue specificity of the hormonal response in sex accessory tissues is associated with nuclear matrix protein patterns. , 1990, Molecular endocrinology.

[49]  Y. S. Kim.  Mucin glycoproteins in gastrointestinal malignancies and metastasis : Mucus glycoproteins in the gastrointestinal tract , 1993 .

[50]  L. Andersson,et al.  Detection of colorectal neoplasia with peanut‐agglutinin(PNA)‐reactive carbohydrate structures in rectal mucus , 1997, International journal of cancer.

[51]  H. Sugimura,et al.  Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. , 2004, Gastroenterology.

[52]  U. G. Dailey.  Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.

[53]  Bao-Ling Adam,et al.  Diagnostic potential of serum proteomic patterns in prostate cancer. , 2003, The Journal of urology.

[54]  D. Ransohoff,et al.  Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. , 2004, The New England journal of medicine.

[55]  M. Becich,et al.  Bladder cancer-associated nuclear matrix proteins. , 1996, Cancer research.

[56]  S. Cole,et al.  Prescreening Evaluation of a Brush-Based Faecal Immunochemical Test for Haemoglobin , 2003, Journal of medical screening.

[57]  R. Dubrow,et al.  Fecal lysozyme: an unreliable marker for colorectal cancer. , 1992, The American journal of gastroenterology.

[58]  W Atkin,et al.  Stool DNA-based colorectal cancer detection: finding the needle in the haystack. , 2001, Journal of the National Cancer Institute.

[59]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[60]  K. Kinzler,et al.  Detection of APC mutations in fecal DNA from patients with colorectal tumors. , 2002, The New England journal of medicine.

[61]  S. Woolf.  A smarter strategy? Reflections on fecal DNA screening for colorectal cancer. , 2004, The New England journal of medicine.

[62]  S. L. Gray.  Fecal occult blood testing for colorectal cancer. , 1992, American pharmacy.

[63]  R. Caprioli,et al.  Proteome analysis of human colon cancer by two‐dimensional difference gel electrophoresis and mass spectrometry , 2004, Proteomics.

[64]  K. Garber.  Debate rages over proteomic patterns. , 2004, Journal of the National Cancer Institute.

[65]  A. Shamsuddin,et al.  A simple mucus test for cancer screening. , 1996, Anticancer research.

[66]  E. Aadland,et al.  Faecal calprotectin: a marker of inflammation throughout the intestinal tract , 2002, European journal of gastroenterology & hepatology.

[67]  D. Rockey,et al.  A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy , 2000, American Journal of Gastroenterology.

[68]  M. Becich,et al.  Identification of nuclear matrix protein alterations associated with renal cell carcinoma. , 1998, The Journal of urology.

[69]  R. Schoen,et al.  Nuclear matrix protein alterations associated with colon cancer metastasis to the liver. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[70]  S. Bingham,et al.  Isolation of exfoliated colonocytes from human stool as a new technique for colonic cytology , 2002, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[71]  Carol Carr,et al.  Meta-analysis of dietary restriction during fecal occult blood testing. , 2001, Effective clinical practice : ECP.

[72]  Takurou Nakayama,et al.  ELISA FOR OCCULT FAECAL ALBUMIN , 1987, The Lancet.

[73]  C. Boland,et al.  Abnormal goblet cell glycoconjugates in rectal biopsies associated with an increased risk of neoplasia in patients with ulcerative colitis: early results of a prospective study. , 1984, Gut.

[74]  R. Dubrow,et al.  Fecal protein markers of colorectal cancer. , 1992, The American journal of gastroenterology.

[75]  U. P. S. T. Force,et al.  Screening for Colorectal Cancer: Recommendation and Rationale , 2002, Annals of Internal Medicine.

[76]  Douglas W Mahoney,et al.  Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia , 2003, American Journal of Gastroenterology.

[77]  A. Adrain,et al.  A comparison of fecal occult-blood tests for colorectal-cancer screening. , 1996, The New England journal of medicine.

[78]  D. Shreeve,et al.  Faecal calprotectin: a marker of inflammation throughout the intestinal tract , 2002, European journal of gastroenterology & hepatology.

[79]  J. Fujimoto.  Gene therapy for liver cirrhosis , 2000, Journal of gastroenterology and hepatology.

[80]  C. Folwaczny,et al.  K- ras Mutations in Sera of Patients with Colorectal Neoplasias and Long-standing Inflammatory Bowel Disease , 2002, Scandinavian journal of gastroenterology.

[81]  F. A. Benko,et al.  Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. , 1997, British Journal of Cancer.

[82]  S. Brand,et al.  Fractalkine-mediated signals regulate cell-survival and immune-modulatory responses in intestinal epithelial cells. , 2002, Gastroenterology.

[83]  R. Schoen,et al.  Identification of nuclear matrix protein alterations associated with human colon cancer. , 2002, Cancer research.

[84]  S. Cole,et al.  Effect of dietary restriction on participation in faecal occult blood test screening for colorectal cancer , 2001, The Medical journal of Australia.

[85]  M. Filipe,et al.  Abnormal patterns of mucus secretion in apparently normal mucosa of large intestine with carcinoma , 1974, Cancer.

[86]  Wen-Shyong Tzou,et al.  Molecular Detection of APC, K-ras, and p53 Mutations in the Serum of Colorectal Cancer Patients as Circulating Biomarkers , 2004, World Journal of Surgery.

[87]  A. Shamsuddin,et al.  Usefulness of galactose oxidase-Schiff test in rectal mucus for screening of colorectal malignancy. , 2001, Anticancer research.

[88]  S R Cole,et al.  A Randomised Trial of the Impact of New Faecal Haemoglobin Test Technologies on Population Participation in Screening for Colorectal Cancer , 2003, Journal of medical screening.

[89]  T. Fujita,et al.  Testing of multiple samples increases the sensitivity of stool decay-accelerating factor test for the detection of colorectal cancer , 2003, American Journal of Gastroenterology.

[90]  Z. Bentwich,et al.  Carcinoembryonic Antigen , 1978 .

[91]  F. A. Benko,et al.  Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. , 2000, Journal of the National Cancer Institute.

[92]  K. Pienta,et al.  Nuclear matrix proteins in normal and breast cancer cells. , 1993, Cancer research.

[93]  T. Wan,et al.  Comparison of Shams' test for rectal mucus to an immunological test for fecal occult blood in large intestinal carcinoma screening. Analysis of a check-up of 6480 asymptomatic subjects. , 1993, Chinese medical journal.

[94]  A. Fendrick,et al.  Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. , 2004, Gastroenterology.

[95]  S. Thibodeau,et al.  Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. , 2000, Gastroenterology.

[96]  K. Kinzler,et al.  Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. , 1992, Science.

[97]  G. Young,et al.  Readability and sensitivity of a new faecal occult blood test in a hospital ward environment: Comparison with an established test , 1992, The Medical journal of Australia.

[98]  S. Curran,et al.  Liver fatty acid binding protein expression in colorectal neoplasia , 2004, British Journal of Cancer.

[99]  B. Levin,et al.  Emerging Technologies in Screening for Colorectal Cancer: CT Colonography, Immunochemical Fecal Occult Blood Tests, and Stool Screening Using Molecular Markers , 2003, CA: a cancer journal for clinicians.

[100]  S. Bingham,et al.  Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool , 2002, The Lancet.

[101]  D. S. St. John,et al.  Interference of plant peroxidases with guaiac-based fecal occult blood tests is avoidable. , 1999, Clinical chemistry.

[102]  M. Meneghini,et al.  Nuclear matrix proteins in human colon cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[103]  S. Goodman,et al.  Detecting colorectal cancer in stool with the use of multiple genetic targets. , 2001, Journal of the National Cancer Institute.

[104]  L. Hoskins.  Mucin degradation in the human gastrointestinal tract and its significance to enteric microbial ecology , 1993 .

[105]  D. Amadori,et al.  Fecal multiple molecular tests to detect colorectal cancer in stool. , 2003, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[106]  Z. Ronai,et al.  K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers--a review. , 2000, Cancer detection and prevention.

[107]  Y. Nagamachi,et al.  A pilot study on the usefulness of a new test for mass screening of colorectal cancer in Japan , 1990, Gastroenterologia Japonica.

[108]  P. Propping,et al.  Detection of APC and k-ras mutations in the serum of patients with colorectal cancer. , 2001, Cancer detection and prevention.